Lupin gets European Commission nod for NaMuscla
"The EC approval follows the positive opinion which was issued by the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), in October 2018 and will apply to all 28 countries of the European Union, Norway, Iceland and Liechtenstein," Lupin said in a BSE filing.
New Delhi: Drug major Lupin recently said that the European Commission (EC) has approved its product NaMuscla, used for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NOM) disorders. Non-dystrophic myotonic disorders are a group of rare, inherited, neuromuscular disorders which cause the inability to relax muscles following voluntary contraction.
"The EC approval follows the positive opinion which was issued by the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), in October 2018 and will apply to all 28 countries of the European Union, Norway, Iceland and Liechtenstein," Lupin said in a BSE filing.
Read Also: Lupin gets USFDA nod for generic schizophrenia drug
The approval makes NaMuscla (mexiletine) the first treatment to be licensed throughout the EU for the symptomatic treatment of myotonia in adults with NOM disorders, the company added.
Lupin said it has ongoing partnering discussions for commercialisation of NaMuscla in European territories outside Germany and the UK.
Lupin said it is preparing for the launch of NaMuscla, which will occur in the initial markets of Germany and the UK in the first quarter of 2019.
The approval was based on a pivotal Phase III clinical study (MYOM EX1) which enrolled 25 participants who were diagnosed with non-dystrophic myotonic disorders and symptomatic myotonia, in addition to bibliographical references, the company said.
Read Also: Lupin receives FDA approval for Clobazam Oral Suspension
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd